Sphera Funds Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.3M | Sell |
62,530
-5,000
| -7% | -$964K | 1.96% | 13 |
|
|
2025
Q4 | $12.4M | Hold |
67,530
| – | – | 2.4% | 8 |
|
|
2025
Q3 | $10.4M | Hold |
67,530
| – | – | 2.19% | 9 |
|
|
2025
Q2 | $9.44M | Sell |
67,530
-20,000
| -23% | -$2.8M | 2.21% | 9 |
|
|
2025
Q1 | $12.9M | Sell |
87,530
-25,000
| -22% | -$3.62M | 2.96% | 6 |
|
|
2024
Q4 | $14.7M | Buy |
112,530
+17,500
| +18% | +$2.45M | 2.67% | 5 |
|
|
2024
Q3 | $14.8M | Hold |
95,030
| – | – | 2.36% | 8 |
|
|
2024
Q2 | $14.8M | Hold |
95,030
| – | – | 2.02% | 9 |
|
|
2024
Q1 | $12.9M | Buy |
95,030
+5,000
| +6% | +$662K | 1.81% | 14 |
|
|
2023
Q4 | $12.1M | Sell |
90,030
-52,500
| -37% | -$6.82M | 1.95% | 14 |
|
|
2023
Q3 | $19.3M | Hold |
142,530
| – | – | 3.52% | 4 |
|
|
2023
Q2 | $20.4M | Hold |
142,530
| – | – | 3.19% | 4 |
|
|
2023
Q1 | $19.8M | Sell |
142,530
-57,500
| -29% | -$7.74M | 3.31% | 5 |
|
|
2022
Q4 | $27.1M | Sell |
200,030
-248,500
| -55% | -$31.2M | 5.82% | 3 |
|
|
2022
Q3 | $49.2M | Buy |
448,530
+49,225
| +12% | +$6.24M | 6.83% | 2 |
|
|
2022
Q2 | $52.8M | Sell |
399,305
-19,104
| -5% | -$2.51M | 5.64% | 3 |
|
|
2022
Q1 | $55.5M | Sell |
418,409
-109,325
| -21% | -$13.1M | 7.85% | 1 |
|
|
2021
Q4 | $61.5M | Sell |
527,734
-118,100
| -18% | -$13.9M | 6.76% | 2 |
|
|
2021
Q3 | $77.6M | Buy |
645,834
+71,997
| +13% | +$8.38M | 6.52% | 2 |
|
|
2021
Q2 | $68.7M | Buy |
573,837
+93,600
| +19% | +$10.3M | 4.65% | 2 |
|
|
2021
Q1 | $47.8M | Buy |
480,237
+135,000
| +39% | +$13.6M | 3.66% | 6 |
|
|
2020
Q4 | $34.5M | Sell |
345,237
-64,763
| -16% | -$6.86M | 3.06% | 9 |
|
|
2020
Q3 | $44.9M | Sell |
410,000
-35,000
| -8% | -$3.89M | 4.42% | 6 |
|
|
2020
Q2 | $47.1M | Buy |
445,000
+160,000
| +56% | +$16.5M | 4.43% | 6 |
|
|
2020
Q1 | $25.5M | Buy |
+285,000
| New | +$26.8M | 3.18% | 9 |
|
|
2019
Q3 | – | Sell |
-385,000
| Closed | -$31.8M | – | 83 |
|
|
2019
Q2 | $31.8M | Buy |
385,000
+35,000
| +10% | +$2.74M | 4.35% | 5 |
|
|
2019
Q1 | $28.3M | Buy |
350,000
+92,500
| +36% | +$7.29M | 2.58% | 10 |
|
|
2018
Q4 | $19.6M | Buy |
+257,500
| New | +$20.1M | 2.2% | 10 |
|
|
2017
Q1 | – | Sell |
-25,000
| Closed | -$1.37M | – | 115 |
|
|
2016
Q4 | $1.37M | Sell |
25,000
-75,000
| -75% | -$4.26M | 0.35% | 73 |
|
|
2016
Q3 | $6.57M | Buy |
+100,000
| New | +$6.54M | 1.07% | 21 |
|
|
2015
Q2 | – | Sell |
-86,637
| Closed | -$5.93M | – | 135 |
|
|
2015
Q1 | $5.93M | Hold |
86,637
| – | – | 0.62% | 31 |
|
|
2014
Q4 | $6.1M | Sell |
86,637
-33,363
| -28% | -$2.39M | 1.04% | 23 |
|
|
2014
Q3 | $8.57M | Buy |
+120,000
| New | +$8.78M | 1.06% | 25 |
|
Other funds holding AZN
IA
VCM
VAM
Sphera Funds Management's AZN Position: Q1 2026 in Review
Sphera Funds Management reduced its AstraZeneca (AZN) stake by 7.4% in Q1 2026, selling an estimated $964K and leaving 62,530 shares worth $12.3M. The position accounts for 1.96% of the portfolio, ranked #13.
Sphera Funds Management first reported a position in AZN in Q3 2014 and has held it in 33 quarters since. The position peaked at $77.6M in Q3 2021. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Sphera Funds Management held 62,530 shares of AstraZeneca worth $12.3M as of Q1 2026.
- Sphera Funds Management sold 5,000 AstraZeneca shares in Q1 2026, an estimated $964K.
- AstraZeneca made up 1.96% of Sphera Funds Management's portfolio in Q1 2026, its #13 holding.
- Sphera Funds Management first reported a position in AstraZeneca in Q3 2014 and has held it in 33 quarters since.
- Sphera Funds Management's AstraZeneca position peaked at $77.6M in Q3 2021.
- 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.